Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Neumora Therapeutics, Inc. (NMRA) had Return on Tangible Equity of -29.77% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-67.99M |
|
-- |
|
-- |
|
$70.94M |
|
$-70.94M |
|
$3.05M |
|
$-67.89M |
|
$-67.89M |
|
$-67.99M |
|
$-67.99M |
|
$-67.99M |
|
$-67.99M |
|
$-70.94M |
|
$-72.07M |
|
161.45M |
|
161.45M |
|
$-0.42 |
|
$-0.42 |
|
| Balance Sheet Financials | |
$254.87M |
|
$0.98M |
|
$1.88M |
|
$256.75M |
|
$28.38M |
|
-- |
|
-- |
|
$28.38M |
|
$228.36M |
|
$228.36M |
|
$228.36M |
|
161.75M |
|
| Cash Flow Statement Financials | |
$-59.45M |
|
$44.16M |
|
-- |
|
$143.36M |
|
$128.07M |
|
$-15.29M |
|
$9.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-59.45M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-29.77% |
|
|
Return on Tangible Equity |
-29.77% |
-26.48% |
|
-29.77% |
|
$1.41 |
|
$-0.37 |
|
$-0.37 |
|